GLAUKOS Corp (GKOS) · Nov 6, 2026 · Other events
No new info
Glaukos’ investor presentation outlines its iDose, Epioxa and pipeline strategy, but introduces no material new financial or operational information.
Glaukos is already in commercialization mode, not waiting for a new strategic inflection. The company’s current story is built around scaling iDose TR in glaucoma and Epioxa in keratoconus, with a large dropless-therapy pipeline behind them. That backdrop was already established in the October 28, 2026 third-quarter update, which reported $211.0 million of revenue, raised 2026 sales guidance to $775–$785 million, and introduced preliminary 2027 sales guidance of $1 billion.
This filing mainly repackages that existing story for investors. It repeats the company’s product architecture, market opportunity, iDose TR adoption case, Epioxa launch infrastructure and early-stage pipeline, including that iDose TR is approved for re-administration and that Epioxa is commercially available. 〔0〕 〔1〕
The pipeline breadth is useful context, but not a new business milestone. The presentation cites 14 disclosed programs, 12 commercialized products and completed enrollment in selected studies, but it does not report a new approval, clinical result, guidance change, financing, partnership or other event that materially changes the operating outlook. 〔2〕 〔3〕
| Figure | Presented value |
|---|---|
| 2025 topline growth (Company overview) | 30% |
| 10-year revenue CAGR (Company overview) | 20% |
| R&D invested since 2018 (Company overview) | $900M |
| Cash and equivalents; no debt (Financial footing) | $340M |
| Preliminary 2027 sales outlook (Financial footing) | $1,000M |
Bottom line: This is a polished reaffirmation of Glaukos’ existing iDose-Epioxa growth narrative, not a fresh catalyst. The business story is intact, but the filing itself barely changes what investors already knew after the October earnings update.
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!